Assurex Health Appoints Chief Financial Officer and Payer Market Executive to Manage Rapid Growth in Personalized Medicine

Assurex Health Appoints Chief Financial Officer and Payer Market Executive to
                 Manage Rapid Growth in Personalized Medicine

PR Newswire

MASON, Ohio, April 2, 2013

MASON, Ohio, April 2, 2013 /PRNewswire/ --AssureRx Health, Inc. today
announced the appointment of Stephen A. Stamp as Senior Vice President & CFO
and Jeffrey P. Bush as Vice President, Payer Markets and Reimbursement to its
leadership team. The management appointments coincide with increasing demand
for GeneSight pharmacogenomic testing services, which support healthcare
providers in medication selection and the management of side effects for
patients with neuropsychiatric and other disorders.

"These management appointments provide us with the financial leadership to
address the next phase of our growth strategy and the payer market expertise
to partner with Medicare, Medicaid, and commercial payers," said James S.
Burns, president and CEO of Assurex Health. "Our value proposition is directed
to demonstrating significant improvements in patient outcomes at substantial
reductions in healthcare utilization. The goal is to build the leading
personalized medicine company offering pharmacogenomic treatment decision
support solutions for neuropsychiatric, pain, ADHD, and other disorders."

Stephen A. Stamp, Senior Vice President & Chief Financial Officer is
responsible for all financial matters at Assurex Health, including financing
strategy and implementation, accounting, tax, M&A activities, and government
contracting. Stephen joins Assurex Health with 30 years of experience in
finance, accounting, business development and operations. He has worked in
multiple public and venture-backed companies both in the US and the UK,
including business to consumer (B2C), business to business (B2B), and
pharmaceutical industries. Stephen has served as Chief Financial Officer of
EZCORP, Inc. (NASDAQ: EZPW), a consumer financial services company; Chief
Operating Officer, Chief Financial Officer, and Executive Vice President
Business Development at Xanodyne Pharmaceuticals, Inc., a specialty
pharmaceutical company; Group Finance Director at Regus PLC, a serviced office
accommodations business; and Group Finance Director at Shire PLC, a specialty
pharmaceutical company focusing on ADHD and other specialty medications.
Earlier in his career, Stephen was an investment banker with Lazard in London,
advising mainly public companies on cross-border M&A and corporate finance.
Prior to Lazard, he worked for KPMG in London where he qualified as a
Chartered Accountant. Stephen received his BA in economics from the University
of Manchester.

Jeffrey P. Bush, Vice President of Payer Markets and Reimbursement is
responsible for establishing coverage and value-based reimbursement with
commercial and governmental payers for Assurex Health products, as well as the
Company's overall strategy for collaborating with payers and payer
stakeholders. Jeff brings to Assurex Health over twenty years of experience in
diagnostics, medical devices, and clinical laboratory testing. Prior to
joining Assurex Health, Jeff served as senior director of Reimbursement
Strategy & Payment Policy at Becton, Dickinson and Company (BD) (NYSE: BDX), a
global medical device and diagnostic system manufacturer, responsible for
reimbursement across BD's three worldwide business segments to establish
coding, coverage, and payment for the company's products in the US and abroad.
While at BD, Jeff was instrumental in the development and passage of reform
legislation that enhanced transparency of the Centers for Medicare and
Medicaid Services (CMS) processes for the coverage and payment of new
diagnostic technologies, and developed quality measurement legislative
language included in the Affordable Care Act of 2010. Prior to BD, Jeff led
CYTYC Corporation's (now Hologic) efforts with US payers that drove adoption
and eventual market dominance of the ThinPrep^® Pap Test. Prior to CYTYC, Jeff
was employed as a certified cytotechnologist in multiple clinical
laboratories. He holds a Bachelor's degree in Chemistry from California State
University, San Bernardino, a Cytotechnology certificate from Loma Linda
University, and a Master of Business Administration from Colorado State

About AssureRx Health, Inc.
AssureRx Health, Inc. is a personalized medicine company that specializes in
pharmacogenomics dedicated to helping physicians determine the right drug for
individual patients suffering from neuropsychiatric and other disorders. The
company was founded to commercialize industry-leading personalized medicine
technology for neuropsychiatric disorders. Mayo Clinic and Cincinnati
Children's Hospital Medical Center are equity holders and technology

About GeneSight
GeneSight is a laboratory developed pharmacogenomic test that uses cutting
edge technology to measure and analyze clinically important genomic variants
in the treatment of psychiatric disorders. The results of the GeneSight report
can help a clinician understand the way a patient's unique genomic makeup may
affect certain psychiatric drugs. The analysis is based on pharmacogenomics,
the study of genomic factors that influence an individual's response to drug
treatments, FDA approved manufacturer's drug labels, peer-reviewed scientific
and clinical publications, and proven drug pharmacology. Quick turnaround
time, combined with a customized report of the patient's genomic makeup,
clinical experience and other factors can help a physician make personalized
drug treatment choices for each patient.

SOURCE AssureRx Health, Inc.

Contact: Stephen E. King, Vice President, Marketing, AssureRx Health, Inc.,
513.701.5000 e-mail:
Press spacebar to pause and continue. Press esc to stop.